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Purpose: Diagnostic biomarkers of pancreatic ductal adenocarcinoma (PDAC) have been used for early detection to reduce 
its dismal survival rate. However, clinically feasible biomarkers are still rare. Therefore, in this study, we developed an 
automated multi-marker enzyme-linked immunosorbent assay (ELISA) kit using 3 biomarkers (leucine-rich alpha-2-
glycoprotein [LRG1], transthyretin [TTR], and CA 19-9) that were previously discovered and proposed a diagnostic model 
for PDAC based on this kit for clinical usage. 
Methods: Individual LRG1, TTR, and CA 19-9 panels were combined into a single automated ELISA panel and tested on 
728 plasma samples, including PDAC (n = 381) and normal samples (n = 347). The consistency between individual panels 
of 3 biomarkers and the automated multi-panel ELISA kit were accessed by correlation. The diagnostic model was 
developed using logistic regression according to the automated ELISA kit to predict the risk of pancreatic cancer (high-, 
intermediate-, and low-risk groups).
Results: The Pearson correlation coefficient of predicted values between the triple-marker automated ELISA panel and the 
former individual ELISA was 0.865. The proposed model provided reliable prediction results with a positive predictive value 
of 92.05%, negative predictive value of 90.69%, specificity of 90.69%, and sensitivity of 92.05%, which all simultaneously 
exceed 90% cutoff value.
Conclusion: This diagnostic model based on the triple ELISA kit showed better diagnostic performance than previous 
markers for PDAC. In the future, it needs external validation to be used in the clinic. 
[Ann Surg Treat Res 2021;100(3):144-153]
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INTRODUCTION
Early diagnosis of any cancer is effective to improve survival 
rate and prognosis [1]. It is especially significant for pancreatic 
ductal adenocarcinoma (PDAC), one of the most lethal cancers 
with 5-year survival rates of 2%–9% [2]. About 80%–85% of PDAC 
is unresectable at the time of diagnosis without any curative 
treatment modalities [3]. There are a number of challenges 
for early diagnosis of pancreatic cancer. Pancreatic cancer 
does not usually show specific symptoms at earlier stages, 
resulting in late diagnosis and advanced stages. It also lacks 
noninvasive diagnostic tests such as blood-based biomarkers. 
The current diagnostic modalities are CT- or MRI-based or 
endoscopic ultrasound biopsy [4], which are not cost-effective 
nor noninvasive. 
Although considerable advances have been made in diagnosis 
and management of PDAC to increase overall survival, there 
is no effective screening test or treatment other than surgical 
resection which is the only possible cure for PDAC so far. 
Therefore, it is important to develop a screening test for 
the general population for early detection of PDAC so that 
diagnosed patients stand a better chance of survival after 
surgical resection of the tumor. This screening test should 
ideally be a cost-effective, fast, and less invasive diagnostic 
modality. 
Biomarkers or tumor markers detected in a simple blood test 
have provided increasing opportunities for screening, early 
diagnosis, prognosis, and monitoring therapy response for 
cancers [5,6]. Although many ‘potential biomarkers’ for PDAC 
have been discovered [7], the CA 19-9 is the only one approved 
by the United States Food and Drug Administration (FDA) for 
pancreatic cancer so far. However, CA 19-9 has a sensitivity of 
70%–80% and a specificity of 82%–90% for PDAC [8,9], and is 
absent in asymptomatic patients [10], 10%–13% of pancreatic 
cancer patients [10,11] and is not tumor-specific [9]. These 
numbers are not high enough to be effective for early detection 
of PDAC. In line with this, there have been increasing efforts 
to combine some biomarkers to find a multi-marker panel with 
improved accuracy and higher sensitivity than one with only 
CA 19-9 [12-15].
Despite effort to identify tumor-specific biomarkers, 
translation of these novel biomarkers into clinical practice 
has been very limited. To successfully bridge the gap 
between the laboratory and clinic, we need precise proteomic 
quantitative technologies and good analytical performance 
of the quantitation [16,17]. There are some assays that had 
been approved by the FDA for certain cancers [18], but none 
of these were introduced for pancreatic cancer except for CA 
19-9. Recently, 2 studies developed a serum multi-biomarker 
microarray for the early detection of PDAC that went through 
external validation on a large cohort [19,20]. However, they were 
still missing some requirements for an ideal screening test, 
such as cost-effectiveness and simplified usage. 
Therefore, in this study, we developed an automated triple-
marker enzyme-linked immunosorbent assay (ELISA) kit for 
simple usage and the diagnostic model, which can achieve high 
diagnostic performance to predict the risk of pancreatic cancer.
METHODS
Overview of study design
The automated multi-biomarker ELISA kit was developed 
using 3 potential biomarkers, leucine-rich alpha-2-glycoprotein 
(LRG1), transthyretin (TTR), and CA 19-9, which were discovered 
in the previous study [19]. Park et al. [19] identified them using 
multiple reaction monitoring-mass spectrometry (MRM-MS), 
and for which external validation was done at multiple centers. 
The triple-marker panel demonstrated better performance than 
that for CA 19-9 alone for distinguishing PDAC from normal, 
other cancers (breast, thyroid, and colorectal cancers), and 
benign pancreatic disease.
We first had to verify the consistency of the dataset between 
the automated multi-panel ELISA kit and the individual-marker 
ELISA panels of the previous study. The correlation between the 
2 datasets was analyzed with the Pearson correlation method. 
Afterward, a prediction model was developed using logistic 
regression (LR) models. The entire data was divided into a 7:3 
ratio of training dataset (n = 511) and test dataset (n = 217) 
by random sampling. Normal and PDAC data were randomly 
divided into the training and test datasets in the same ratio.
From the LR diagnostic model, 3 risk groups were classified 
using thresholds. The conditions for finding the optimal 
combination of 2 thresholds were evaluated by introducing 4 
measures, negative predictive values (NPV), positive predictive 
values (PPV), sensitivity (Sen), and specificity (Spe). 
This study was approved by the Institutional Review Boards 
of all participating institutions (SNUH surgery H-0901-010-267, 
SNUH internal medicine H-0412-138-005 and H-0412-138-006, 
SNUH HSGC H-1305-573-489 and C-1301-095-458, YSH 4-2013-
0725, NCC NCCNCS13818, SMC 2008-07-065, and AMC 2013-
1061) and biospecimens were collected from participants who 
provided informed consent.
Study population
A total of 728 samples were collected between January 2011 
and December 2013, including 347 normal and 381 PDAC from 
multiple centers in Korea (Seoul National University Hospital or 
Seoul National University Hospital Healthcare System Gangnam 
Center, National Cancer Center, Asan Medical Center, Samsung 
Medical Center, and Yonsei Severance Hospital). The normal 
samples were defined by participants who were healthy or those 
with gallstones or cholecystitis without severe inflammation. 
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They did not possess any malignancies or other serious health 
conditions. Age, sex, body mass index (BMI), smoking, and 
alcohol history were considered for all samples. All stages of 
PDAC were included and the stage of the disease was classified 
as per the 7th edition of American Joint Committee on Cancer. 
The demographics are listed in Table 1. 
Automated ELISA kit and consistency between 
individual vs. multi-marker panel datasets
ELISA was used for quantitative analysis of proteins in serum 
samples. We first developed an automated multi-panel ELISA 
kit that included LRG1, TTR, and CA 19-9 panels in 1 ELISA 
microwell plate. Instead of generating 3 panels individually in 
different ELISA kits and combining the results in an additional 
process, 1 microwell could have the functionality to screen 
for all 3 biomarkers at once and make the test faster. This 
kit was tested for all 728 plasma samples (Human Pancreatic 
Cancer Trio ELISA kit, Abfrontier, Seoul, Korea) using the 
Dynex-DS2 (Dynex Tech. Inc., Chantilly, VA, USA). Dynex-
DS2 is an automated ELISA machine that includes transfer, 
dispensing, washer, incubator, reader, and analysis systems, 
all in 1 machine. The test was performed according to the 
manufacturer’s recommendations. Briefly, LRG1, CA 19-9, and 
TTR were diluted 2,000-, 4-, and 10,000-fold, respectively, using 
the designated solutions. The standard, control reagents, and 
plasma samples (each 100 μL) were loaded onto assigned wells. 
The standard and control reagents were duplicated. The wells 
were incubated at room temperature for 2 hours. After the wells 
were washed 3 times, the conjugate (100 μL) was added and 
incubated for 1 hour at room temperature. Again, after the wells 
were washed 3 times, the substrate solution (100 μL) was added 
and incubated at room temperature for 30 minutes. The stop 
solution (100 μL) was added to cease the reaction. The optical 
density was measured at 540 or 570 nm. The concentration was 
obtained by 4-parameter logistic curve fit, multiplied by the 
dilution factors. 
The triple-marker ELISA test results were compared with the 
individual ELISA test results based on the 3 markers, LRG1, 
TTR, and CA 19-9, generated in the previous study [19]. At this 
time, only common data from the same patient were used 
to check the experimental consistency between the single-
panel and multi-panel ELISA kits (Supplementary Table 1). The 
Pearson and Spearman correlation coefficients were calculated 
for checking consistency between 2 ELISA datasets. The log-
transformed observed values of each marker were investigated 
first and then the values predicted by the prediction model 
were considered.
Classification of low-, intermediate-, and high-risk 
groups
The diagnostic or risk prediction model was developed 
using the LR model. Based on the predicted probability of 
developing pancreatic cancer from the LR model, the patients 
were classified into low-, intermediate-, and high-risk groups by 
Table 1. Demographics of study population
Variable Total PDAC Normal P-value
No. of patients 728 381 347
Age (yr) 59.4 ± 9.6 61.6 ± 10.3 56.9 ± 8.1 <0.001
Male sex 435 (58.5) 241 (63.3) 194 (55.9) 0.040
Body mass index (kg/cm2) 23.4 ± 3.0 22.9 ± 3.0 23.8 ± 3.0 <0.001
Alcohol 425 (58.4) 158 (41.5) 267 (76.9) <0.001
Smoking 287 (39.4) 146 (38.3) 141 (40.6) 0.523




1.2 ± 0.8 
(n = 198)
0.046
Initial CA 19-9 (U/mL) 2,024.5 ± 10,140.8
(n = 578)
3,073.3 ± 12,383.1 
(n = 380)
11.5 ± 33.1 
(n = 198)
<0.001
Stage of PDAC - - -
   I 20 (5.2)
   II 228 (59.8)
   III 30 (7.9)
   IV 100 (26.2)
Automated ELISA triple-marker panel
   LRG1 (ng/mL) 10,260.4 ± 6,361.6 12,421.6 ± 7,656.9 7,887.4 ± 3,139.3 <0.001
   TTR (ng/mL) 237,267.2 ± 118,740.2 181,175.1 ± 60,287.7 298,855.3 ± 135,514.9 <0.001
   CA 19-9 (U/mL) 465.0 ± 1,755.8 875.9 ± 2,354.2 13.8 ± 19.8 <0.001
Values are presented as number only, mean ± standard deviation, or number (%). 
PDAC, pancreatic ductal adenocarcinoma; ELISA, enzyme-linked immunosorbent assay; LRG1, leucine-rich alpha 2 glycoprotein; 
TTR, transthyretin.
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2 thresholds δ1 and δ2. In order to choose the values of δ1 and δ2 
systematically, we considered 4 measures: NPV, PPV, Sen, and 
Spe. Note that from normal and PDAC groups, the classification 
model results in 3 risk groups (low, intermediate, and high). 
For simplicity, we used modified versions of NPV, PPV, Sen, 
and Spe by considering only the high- and low-risk groups. 
For normal group, let n11 represent the count of predicted 
probability smaller than δ1, n12 the count between δ1 and δ2, and 
n13 the count larger than δ2 For PDAC, let n21, n22, and n23 be the 
corresponding counts, respectively. The 4 modified measures 
are calculated without the intermediate-risk group as follows:
NPV =
n11 , PPV = 
n23 , Sen = 
n23 , Spe = 
n11
n1 + n21 n13 + n23 n21 + n23 n11 + n13
In order to choose the optimal values of δ1 and δ2, we 
changed these values from 0.01 to 0.99 by 0.01. We found the 
optimal combinations which yielded the highest average for the 
4 measures under the conditions that all 4 measures exceeded 
the cutoff values such as 85%, 90%, and 95%, respectively. Since 
4 measures are calculated excluding the intermediate-risk 
group, performance is highly dependent on the count of the 
intermediate-risk group. 
Statistical analysis
The demographic analysis and graphical work was performed 
using R ver. 3.6.2 (R Foundation for Statistical Computing, 
Vienna, Austria). Categorical variables of the normal and PDAC 
groups were compared via the chi-square test. The continuous 
variables were summarized using the means and standard 
deviations and compared via the Student t-test. Two-sided 
P-values of <0.05 were considered to be significant. 
RESULTS
Clinical characteristics of patients
Clinical characteristics of PDAC patients and normal controls 
are shown in Table 1. Age and levels of initial CEA and initial 
CA 19-9 were significantly higher in PDAC group, whereas 






















































































































Fig. 1. The relationship between individual panels and multi-panel enzyme-linked immunosorbent assay (ELISA) kit datasets. 
(A) The scatter plot of predication values from the individual panels and multi-panel ELISA kit datasets. The red box indicated 
common regions of low- and high-risk groups using 2 thresholds. The level of log-transformed (B) LRG1, (C) TTR, and (D) CA 
19-9 were measured by individual and multi-panel ELISA kits. LRG1, leucine-rich alpha 2 glycoprotein; TTR, transthyretin.
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BMI was significantly lower in PDAC than normal group, all of 
which were consistent with the characteristics of PDAC. The 
rate of drinking alcohol was significantly lower in PDAC group. 
Also, the levels of automated ELISA kit of each markers were 
significantly higher in PDAC group than normal group, which 
well-discriminated the pancreatic cancer and normal. The levels 
of CA 19-9 and LRG 1 by the automated ELISA kit increased, and 
TTR decreased in PDAC group (Supplementary Fig. 1). 
Consistency of multi-marker ELISA panel to 
individual-marker ELISA panel dataset
Consistency was confirmed along with the comparison 
between the individual biomarker ELISA kit data identified in 
the previous study [19] and the multi-panel ELISA kit data in 
this study. Pearson correlation of predicted values for PDAC 
by LR as the prediction model showed a high correlation of 
0.865 between the 2 datasets (Fig. 1 and Supplementary Table 
2). In the scatter plot of predicted values using the individual 
panel and multi-panel ELISA kit datasets, the distribution of 
predicted values for PDAC was divided into 3 groups, and any 2 
threshold values for dividing them can be identified. Moreover, 
correlations of log-transformed 3-marker LRG1, CA 19-9, and 
TTR to individual and multi-marker data set were also high as 
predicted value (Fig. 1B–D).
Diagnostic model development 
The diagnostic model for PDAC was developed using LR 
based on the multi-panel ELISA kit for 2 categories of normal/
PDAC. A total of 5 variables including covariates, sex and age, 
and 3 biomarkers, CA 19-9, LRG1, and TTR, were selected to 
construct an LR model for diagnostics. The fitted LR model is 
given as follows:
log ( P (PC) )= 51.03 + 0.04 (Age) + 1.19 (Sex M) − 5.12 log (TTR) 1 − P (PC)
+ 0.61 log (CA 19-9) + 0.80 log (LRG1)
Optimizing threshold combination and prediction 
performance
For the optimal combination of δ1 and δ2, Table 2 shows 
the 4 evaluation measures and the numbers of risk groups for 
the given the cutoff values. As the cutoff values decrease, the 
numbers of high- and low-risk groups increase, while that of the 
intermediate-risk group decreases. When the cutoff value was 
95%, for example, there were 216 subjects in the intermediate-
risk group, and the number of intermediate-risk group became 
68 and 1 as the cutoff values were reduced to 90% and 85%. 
For a real clinical application, it would be important to have 
enough numbers of high- and low-risk groups in the prediction 
results. Unfortunately, the greater the size of high- and low-risk 
groups, the smaller the evaluation measures. As a compromised 
solution for practical application, the 90% cutoff value was 
chosen which provided the optimized threshold values; (δ1, δ2) 
= (0.32, 0.60) (Fig. 2B). For these thresholds, the values of NPV, 
PPV, Sen, Spe were 90.69, 92.05, 92.05, and 90.69, respectively 
and its mean was 91.37 (Table 2). 
In order to evaluate the performance of the proposed 
diagnostic model, we applied this model to the test dataset 
using the same optimal threshold value; (δ1, δ2) = (0.32, 0.60). 
For these thresholds, the values of NPV, PPV, Sen, Spe were 
91.57, 90.48, 93.14, and 88.37, respectively and its mean was 
90.89, as shown in the last column of Table 2. 
Table 2. Optimization of thresholds
Data set Training dataset Test dataset
Cutoff for evaluation measures (%) 95 90 85 90
Four evaluation measures
   NPV 95.2381 90.6863 85.4251 91.5663
   PPV 97.3684 92.0502 87.8327 90.4762
   Sensitivity 97.3684 92.0502 86.5169 93.1373
   Specificity 95.2381 90.6863 86.8313 88.3721
Mean of measures 96.3033 91.3682 86.5615 90.8880
No. of risk group
   Low 105 204 247 83
   Intermediate 216 68 1 29
   High 190 239 263 105
Threshold
   δ1 0.08 0.32 0.46 0.32
   δ2 0.83 0.6 0.47 0.60
Performance of the predicted model was compared with various cutoff values of evaluation measures and verified with training and 
test data set. The thresholds that satisfied high diagnostic evaluation measures and the lowest number of intermediate-risk group at the 
same time were selected.
NPV, negative predictive values; PPV, positive predictive values.
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Table 3 shows a 2 × 3 contingency table. For the training 
dataset, 75.82% of normal subjects were classified into the 
low-risk group, while 82.40% of PDAC patients into the high-
risk group. On the other hand, for the test dataset, 73.79% of 
normal subjects were classified into the low-risk group, while 
83.33% of PDAC patients into the high-risk group. The predicted 
percentages of intermediate-risk groups were 16.39% and 10.49% 
for normal and PDAC groups, respectively for the training 
dataset.
The performance of the diagnostic model was also evaluated 
by stages, comparing early and late stages of PDAC (Table 4). 
The proposed model also showed high diagnostic performance 
in both stage I/II and stage III/IV, similar to the performance in 
all stages. Moreover, when applied to the model, both early and 
late stages were effectively classified into low-, intermediate-, 
and high-risk groups (Fig. 2C–F).
DISCUSSION 
In this multicenter biomarker study, we developed the 
automated triple-marker kit using ELISA assay and the 
diagnostic model for PDAC. The diagnostic model using the 
automated ELISA kit had better diagnostic performance (all of 
NPV, PPV, Sen, and Spe over 90%) than known performance 
of CA 19-9 alone from previous studies (Sen and Spe 70–90%). 
In addition, the proposed model was well adopted even in the 
early stages of PDAC, which were usually hard to detect in the 
clinic.
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Fig. 2. Optimized threshold combination for the enzyme-linked immunosorbent assay (ELISA) triple-marker prediction model. 
The box plot (A) and density plot (B) for all stages showed that the high-risk group had a predicted value close to 1 and the 
low-risk group has a value close to 0 using automated ELISA triple-marker kit. The intermediate-risk group was in between δ1 
and δ2. The diagnostic model was evaluated for the early stage (C, D) and the late state (E, F). NL, normal; PDAC, pancreatic 
ductal adenocarcinoma. 
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A blood-based cancer detection test is minimally invasive, less 
expensive than imaging diagnostic tools, and somewhat simple 
and convenient. For this reason, cancer-specific biomarkers 
have emerged as an important screening tool [21]. In addition, 
the multi-biomarker panels have worked as better alternatives 
to single biomarker ones due to better diagnostic performance 
[22]. There are several studies [12-14,20,23], including the study 
previous to this one [19], that introduced multi-marker panels 
for pancreatic cancer and demonstrated superior Sen and Spe to 
that of CA 19-9 (Supplementary Table 3). However, most panels 
have been verified at a single institution. We used CA 19-9, 
LRG1, and TTR panels that had already demonstrated multi-
institutional external validation from the previous biomarker 
discovery study [19]. 
Once potential biomarkers are identified, the next step 
is to develop a model for diagnostic accuracy, which would 
eventually be used in routine clinical practice [18,21]. Currently, 
there are biomarker-based models for certain cancers, approved 
for clinical practice [1,18,22,24]. For example, in ovarian cancer, 
OVA1 is an example of a successful translation of multi-
biomarker panel to clinical use that has been cleared by the 
FDA [25]. OVA1, consisting of CA125, TTR, apolipoprotein A1, 
beta 2 microglobulin, and transferrin, demonstrated a Sen of 
96% and NPV of 98% for identifying high-risk ovarian tumors 
[26]. There are no prediction models for pancreatic cancer yet 
in a clinical setting. But most recently, a microarray-based 
biomarker test (IMMray PanCan-d, Immunovia, Lund, Sweden), 
which achieved external validation, was introduced and was 
about to be approved by the FDA and marketed [20]. However, 
due to its high cost, it may not be practical to be used as a 
screening tool. Therefore, the PDAC diagnostic model with only 
3 biomarkers, CA 19-9, LRG1, and TTR, described in this study 
would confer the advantage of being less expensive and more 
practical. 
The algorithm for risk calculation needs risk stratification 
to identify actual likelihood of malignancy. To discriminate 
normal and PDAC, we classified risks into 3 groups (low, 
intermediate, and high) instead of a binary discrimination. We 
included the intermediate-risk group for a specific reason. For 
example, if risk is 40%, it would be ambiguous to know whether 
there is a low or high risk to get pancreatic cancer. Inclusion of 
the intermediate-risk group would differentiate the low- and 
high-risk groups incontestably. If individuals are positioned in 
the high-risk group, they are highly suspicious of having PDAC 
and thus need more precise examination or other interventions 
for treatment. If they are placed in the intermediate-risk group, 
which implies moderate risk or above, they need further 
radiologic examination or follow-up tests to ascertain any 
possibility of cancer. This may result in early detection and 
treatment planning for pancreatic cancer. The low-risk groups 
may not need further checkups. 
The levels of tumor markers are known to be varied by stages 
of cancer with usually higher detection rate at late stage [27]. 
Thus it is important to know if our ELISA kit and model can 
discriminate the cancer and the normal even at early stages. 
When we analyzed NPV, PPV, Sen, and Spe for early and late 
stages separately, those values of both conditions showed 
Table 4. Comparison of performance between normal vs. PDAC early stage and normal vs. PDAC late stage patients
Data set
Normal vs. PDAC all Normal vs. PDAC I/II Normal vs. PDAC III/IV
Training Test Training Test Training Test
Four evaluation measures
   NPV 90.6863 91.5663 92.9648 93.8272 97.3684 97.4359
   PPV 92.0502 90.4762 87.8205 85.5073 81.3726 78.2609
   Sensitivity 92.0502 93.1373 90.7285 92.1875 94.3182 94.7368
   Specificity 90.6863 88.3721 90.6863 88.3721 90.6863 88.3721
Mean of measures 91.3682 90.8880 90.55 89.9735 90.9364 89.7014
Performance was compared between normal vs. PDAC stage I/II (early) and normal vs. PDAC stage III/IV (late) patients. 
PDAC, pancreatic ductal adenocarcinoma; NPV, negative predictive values; PPV, positive predictive values. 
Table 3. The 2 × 3 classified table of normal and PDCA 






   Low 185 (75.82) 19 (7.12)
   Intermediate 40 (16.39) 28 (10.49)
   High 19 (7.79) 220 (82.40)
   Total 244 (100) 267 (100)
Test dataset 
   Low 76 (73.79) 7 (6.14)
   Intermediate 17 (16.50) 12 (10.53)
   High 10 (9.71) 95 (83.33)
   Total 103 (100) 114 (100)
Values are presented as number (%). 
PDAC, pancreatic ductal adenocarcinoma. 
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similar evaluation measures as all stages. However, PPV of both 
conditions showed somewhat lower values than all stages, 
which could be explained by decreased sample sizes as we 
divided them. Moreover, our model was nicely applied to both 
early and late stages, discriminating the normal and the cancer. 
In biomarker studies, assay development should not only 
concentrate on diagnostic and clinical performance but also 
on time- and cost-effectiveness. It is desirable for assays to 
be precise, less time consuming, inexpensive, and have the 
ability to profile large amounts of proteins at a time [28,29]. The 
selection of a method may be dependent on the government 
healthcare support system, laboratory capacities and other 
factors. In this study, ELISA was used to quantitate the amount 
of biomarker proteins in serum samples instead of MRM-
MS, which was formerly used in the study by Park et al. [19]. 
The MRM-MS is a high throughput and sensitive protein-
quantitating method that was also cost-effective and fast for the 
validation of the triple-marker panel [30]. The MRM-MS requires 
only small sample volumes, about 20 μL, and has no limitation 
on the number of markers in the multi-marker panel [30]. 
However, since this innovative device cannot analyze CA 19-9 
and is not yet available in general clinics but only equipped in 
only laboratories, we needed a compromise between a real life 
and ideal setting. Furthermore, to make a panel kit simpler, we 
made an effort to combine 3 biomarker panels into 1 microwell. 
In this way, we could achieve a faster and less expensive assay. 
For the practical use of the biomarker panels, ELISA technique 
was used to build the diagnostic model, making it minimally 
invasive and cost-effective. 
In spite of the high diagnostic performance of the model, 
there were some limitations. First, samples were collected 
retrospectively due to the retrospective nature of the research. 
Moreover, since multi-institutional samples were limited within 
Korea only, the model might not be applicable to the general 
population elsewhere. Also, the training sets and test sets for 
construction of the model were separate portions of the same 
dataset. Ideally, models should be trained, tested, and validated 
with different sets of data. However, due to the low incidence 
of PDAC, there were limitations in collecting samples that were 
large enough in size. Another limitation of the study was that 
diagnostic performance was only evaluated between PDAC 
and normal. Nevertheless, we need further experimentation 
to discriminate PDAC from other groups, such as other cancers 
and benign pancreatic disease, for which we are already 
preparing in another study. Since the purpose of this study 
was to analyze the diagnostic performance of the automated 
ELISA kit and the development of the models, we will focus on 
a large scale validation trial with the automated ELISA kit and 
the diagnostic model to prove its safety and efficacy in the next 
study. 
The triple ELISA diagnostic prediction model in this study 
satisfied the requirements of an ideal screening test, of being 
simple to use, being less expensive, having reduced turnaround 
time, and more importantly, showing high diagnostic 
performance with NPV, PPV, Sen, and Spe, all greater than 90%. 
We demonstrated the performance of the diagnostic model for 
more than 700 samples collected from multiple centers in South 
Korea. This study, thus, proposes a model that could predict 
the risk of pancreatic cancer (low, intermediate, and high) for 
general population and could potentially replace the previous 
tumor marker CA 19-9 for diagnosing pancreatic cancer. 
However, it needs external validation and further investigation.
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